Levy Adam D. 4

What Happened
Adam D. Levy, Chief Financial Officer of Acrivon Therapeutics (ACRV), was granted a derivative award covering 132,925 shares on 2026-03-01. The Form 4 lists the acquisition price as $0.00 (an awarded option), so no cash changed hands at grant. This is an equity award (not a sale or open-market purchase) and is a routine compensation-related grant.

Key Details

• Transaction date: 2026-03-01; Form 4 filed: 2026-03-03 (appears filed within the usual two-business-day window).
• Transaction type: A (award/acquisition of derivative security) — 132,925 shares reported at $0.00.
• Vesting: 25% vests on March 1, 2027; remaining shares vest in 36 substantially equal monthly installments thereafter, subject to continuous service (per footnote).
• Shares owned after transaction: not specified in the provided filing excerpt.
• No indication of an immediate exercise or sale — this is a grant of options/rights, not a cashless exercise or disposition.

Context
This is a compensation-related option award that vests over time; such grants are common for executives and do not reflect an immediate purchase or sale. Because the award is a derivative (option), Levy does not receive freely tradable shares until vested and any exercise conditions are met. The filing appears timely (filed two days after the grant), and there are no special plans (e.g., 10b5-1 or tax withholding) noted in the excerpt.